Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

African-American Heart Failure Trial

This study has been completed.
Sponsor:
Information provided by:
Nitromed
ClinicalTrials.gov Identifier:
NCT00047775
First received: October 18, 2002
Last updated: June 23, 2005
Last verified: October 2004

October 18, 2002
June 23, 2005
May 2001
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
African-American Heart Failure Trial
Not Provided
A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure.
The overall objective is confirmation of BiDil’s Safety and Efficacy in African-American (AFA) Patients with Moderate to Severe Symptomatic Heart Failure.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Congestive Heart Failure
Drug: BiDil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1100
August 2004
Not Provided
  • African American male or female 18 years or older.
  • NYHA Class 3 & 4.
  • Have either a resting LVEF less than or equal to 35% (by any method) or a resting LVIDD greater than 2.9 cm/m2 BSA (or greater than 6.5 cm) with LVEF less than 45% (by echocardiogram).
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00047775
A-HeFT
Not Provided
Not Provided
Not Provided
Not Provided
Nitromed
Not Provided
Study Chair: Anne L. Taylor, M.D. University of Minnesota - Clinical and Translational Science Institute
Nitromed
October 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP